A Randomized, Double-Blind, Placebo-Controlled 52-Week Studyto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2012
This article has no abstract
Epistemonikos ID: 0767d38233a5b45aa119f318c60784e3cbc3f983
First added on: Apr 17, 2025